Longitudinal cohort study; measurements before start of systemic therapy and one year later.
Aged 18-39 years at cancer diagnosis
Having a histologically and/or cytologically confirmed cancer diagnosis, including leukemia, (non-)Hodgkin lymphoma, testicular cancer, osteosarcoma, Ewing sarcoma, breast cancer, and cervical cancer.
Scheduled to start systemic therapy with curative intent. Allowed treatments (concurrent or sequential) are: surgery, radiotherapy, chemotherapy, antibodies.
patients who are not able to understand the patient information letter and informed consent form
patients who will be treated with immune checkpoint inhibitors or targeted therapy with inhibitors of angiogenesis
patients who have been treated with systemic therapy or radiotherapy for a previous malignancy (exceptions: in situ carcinoma of the cervix or uterus and adequately treated basal and squamous cell carcinoma of the skin).
University Medical Center Groningen
Lead sponsor
UMCG Kanker Researchfonds
Collaborator